Top Markets
Coin of the day
F-star Therapeutics, Inc. F-star Therapeutics, Inc.

F-star Therapeutics, Inc.

FSTX
Rang in Aktien #21013
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated... F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to inventing tetravalent bispecific antibodies for the treatment of cancer, particularly within the field of immuno-oncology. The company's primary investigational product, FS118, is currently in a Phase 2 proof-of-concept trial, evaluating its efficacy in head and neck cancer patients who have acquired resistance to PD-1/PD-L1 therapies. F-star is also advancing FS222, a bispecific antibody designed to simultaneously target the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, through its initial Phase 1 human clinical study. Moreover, two additional drug candidates, FS120 and SB 11285, are undergoing Phase 1 clinical evaluation for patients with advanced malignancies. Founded in 2002, F-star Therapeutics, Inc. has its corporate headquarters situated in Cambridge, United Kingdom.
Aktienkurs
$7.12
Zuletzt synchronisiert: 2023-03-08
Marktkapitalisierung
$117.03M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
GB
Handel F-star Therapeutics, Inc. (FSTX)

Kategorie

Dividendenhistorie für F-star Therapeutics, Inc. (FSTX)
F-star Therapeutics, Inc. (Aktienkürzel: FSTX) zahlte insgesamt 0 Dividenden.
Die Summe aller Dividenden (angepasst an Aktiensplits) beträgt: 0.00
Dividendenrendite (TTM): 0
Dividendenzahlungen für F-star Therapeutics, Inc. (FSTX) von 2026 bis 2026
Jährliche Dividendenzahlungen
Jahr Dividende (angepasst an Aktiensplits) ändert
Nicht genügend Daten für die angegebenen Daten.
Liste aller Dividendenzahlungen
Jahr Dividende ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenzahlungen ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Dividendenzahlungen Land
0.00%
US
0.00%
NL
0.00%
US
64.00%
AU
0.00%
CH